Background Advanced pancreatic cancer confers poor prognosis and treatment
advancement has been slow. Recent randomized clinical trials (RCTs) have demonstrated …

4604 Background: To date, only limited toxicity data are available for the combination of
erlotinib (E; 150 mg/d) with either gemcitabine (G) or capecitabine (C) as first-line therapy for …

Abstract Learning Objectives After completing this course, the reader will be able to:
Evaluate the existing chemotherapeutic options for advanced pancreatic cancer. Interpret …

The introduction of novel agents targeted to specific molecular targets of cancer cells offers
more treatment options and improvement in outcome for exocrine pancreatic …

Background Pancreatic cancer is one of the most aggressive malignancies and
chemotherapy is an effective strategy for advanced pancreatic cancer. Gemcitabine (GEM) is …

4099 Background: Patients with advanced pancreatic cancer who fail first-line gemcitabine-
based therapy have no standard treatment options. Capecitabine (CAPE) has activity in …

Background Gemcitabine (GEM) is used as a standard first-line drug to effectively alleviate
symptoms and prolong survival time for advanced pancreatic cancer. Most randomized …

Objectives Fluoropyrimidine-based regimens have been investigated as the second line
chemotherapy in patients with advanced pancreatic cancer refractory to gemcitabine. We …

Background Gemcitabine (GEM) is the standard first-line chemotherapy that provides limited
clinical benefits for patients with locally advanced/metastatic pancreatic adenocarcinoma …

Objective We retrospectively compared the efficacy and toxicity of gemcitabine combination
with capecitabine or erlotinib in unresectable pancreatic cancer to know whether the …